NMD4C Welcomes Two New Staff Members
The NMD4C recently welcomed two new members to the network coordination team! Victoria Larocca, PhD joins us as the new Training and Curriculum Coordinator, and Zainab Adamji joins as the Outcome Measures and Natural History Coordinator.
Victoria Larocca, PhD | Training and Curriculum Coordinator
Victoria is a dedicated knowledge mobilization specialist with a passion for advancing health research and education. She earned her Ph.D. and M.Sc. in Kinesiology and Health Science from York University in 2022 and 2018, respectively, following her Bachelor of Education from Brock University in 2016.
Throughout her academic journey, Victoria has immersed herself in health psychology and clinical research. With her experience and education in health research, Victoria is committed to advancing the education and curriculum for neuromuscular trainees as well as advancing the research conducted at Muscular Dystrophy Canada.
Zainab Adamji | Outcome Measures and Natural History Coordinator
Zainab is a dedicated knowledge mobilization specialist with a passion for translating research into practical applications and influencing policy. She earned her Honours B.Sc. in Biology, specializing in Biotechnology, from the University of Waterloo in 2020, followed by an MSc in Molecular Science from Toronto Metropolitan University in 2022. During her academic studies, Zainab researched lysosome dysfunction and its intricate impacts on organelle cross-talk. Zainab has supported numerous research and advocacy initiatives at Muscular Dystrophy Canada and has further honed her expertise through the MobilizeU knowledge mobilization certification program at York University.
Within her role at the NMD4C, Zainab works to coordinate NMD outcome measures, developing training modules and provide training on validated NMD outcome measures, and selecting patient-reported outcome measures to be captured in post-market surveillance patient registries.
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.